Sign In
Buy CRIS
$4.75
-0.210 (-4.23%)
At Close: Jul 13, 2026
Curis Consents First Six Patients in TakeAim CLL Study
09:30am, Monday, 06'th Jul 2026
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FL
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected Decem
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
04:20am, Wednesday, 13'th May 2026
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Curis Provides First Quarter 2026 Business Update
04:00pm, Tuesday, 12'th May 2026
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
05:11pm, Tuesday, 05'th May 2026
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
09:46am, Tuesday, 28'th Apr 2026
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per s
Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 15'th Apr 2026
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
06:02pm, Thursday, 19'th Mar 2026
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Curis Provides Fourth Quarter 2025 Business Update
04:00pm, Thursday, 19'th Mar 2026
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
SecurityBridge Releases the Cybersecurity Resilience Index for SAP (CRIS) to Set the Standard for SAP Security Maturity Benchmarking
09:02am, Tuesday, 17'th Mar 2026
INGOLSTADT, Germany--(BUSINESS WIRE)--SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the release of the Cybersecurity Resilience Index for SAP (CRIS), an indust
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
04:27pm, Thursday, 12'th Mar 2026
LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and
Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS)
01:10am, Thursday, 05'th Mar 2026
eXoZymes (NASDAQ: EXOZ - Get Free Report) and Curis (NASDAQ: CRIS - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
08:00am, Friday, 09'th Jan 2026
Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
08:45am, Wednesday, 07'th Jan 2026
LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and F
